<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Traumatology and Orthopedics of Russia</journal-id><journal-title-group><journal-title xml:lang="en">Traumatology and Orthopedics of Russia</journal-title><trans-title-group xml:lang="ru"><trans-title>Травматология и ортопедия России</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2311-2905</issn><issn publication-format="electronic">2542-0933</issn><publisher><publisher-name xml:lang="en">Vreden National Medical Research Center of Traumatology and Orthopedics</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">17487</article-id><article-id pub-id-type="doi">10.17816/2311-2905-17487</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Reviews</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Обзоры</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="zh"><subject>Reviews</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Role of Gene Polymorphisms in the Development of Aseptic Loosening of Knee and Hip Prostheses: A Review</article-title><trans-title-group xml:lang="ru"><trans-title>Роль генных полиморфизмов в развитии асептической нестабильности эндопротезов коленных и тазобедренных суставов: обзор литературы</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title/></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-3489-3555</contrib-id><name-alternatives><name xml:lang="en"><surname>Kamenskiy</surname><given-names>Alexandr D.</given-names></name><name xml:lang="ru"><surname>Каменский</surname><given-names>Александр Дмитриевич</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alexkamenskiyvm@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-0919-211X</contrib-id><name-alternatives><name xml:lang="en"><surname>Don'kina</surname><given-names>Alexandra I.</given-names></name><name xml:lang="ru"><surname>Донькина</surname><given-names>Александра Ильинична</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alexandradonkina@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-2591-0949</contrib-id><name-alternatives><name xml:lang="en"><surname>Parakhin</surname><given-names>Yuri V.</given-names></name><name xml:lang="ru"><surname>Парахин</surname><given-names>Юрий Вениаминович</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>parachinyuri@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-0274-0670</contrib-id><name-alternatives><name xml:lang="en"><surname>Kovtun</surname><given-names>Olga G.</given-names></name><name xml:lang="ru"><surname>Ковтун</surname><given-names>Ольга Григорьевна</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>miss.olga.kovtun@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4201-4577</contrib-id><name-alternatives><name xml:lang="en"><surname>Parshikov</surname><given-names>Mikhail V.</given-names></name><name xml:lang="ru"><surname>Паршиков</surname><given-names>Михаил Викторович</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>parshikovmikhail@gmail.com</email><xref ref-type="aff" rid="aff5"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Russian University of Medicine</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Российский университет медицины» Минздрава России</institution></aff><aff><institution xml:lang="zh"></institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Pirogov Russian National Research Medical University</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России</institution></aff><aff><institution xml:lang="zh"></institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Semashko Railroad Clinical Hospital of JSC Russian Railways</institution></aff><aff><institution xml:lang="ru">ЧУЗ «Клиническая больница “РЖД-Медицина” им. Н.А. Семашко»</institution></aff><aff><institution xml:lang="zh"></institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России</institution></aff><aff><institution xml:lang="zh"></institution></aff></aff-alternatives><aff-alternatives id="aff5"><aff><institution xml:lang="en">Russian University of Medicine</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Российский университет медицины» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2025-02-12" publication-format="electronic"><day>12</day><month>02</month><year>2025</year></pub-date><pub-date date-type="pub" iso-8601-date="2025-03-12" publication-format="electronic"><day>12</day><month>03</month><year>2025</year></pub-date><volume>31</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><issue-title xml:lang="zh"/><fpage>144</fpage><lpage>156</lpage><history><date date-type="received" iso-8601-date="2024-03-09"><day>09</day><month>03</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-05-02"><day>02</day><month>05</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Эко-Вектор</copyright-statement><copyright-statement xml:lang="zh">Copyright ©; 2025,</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://journal.rniito.org/jour/article/view/17487">https://journal.rniito.org/jour/article/view/17487</self-uri><abstract xml:lang="en"><p><bold>Background<italic>.</italic></bold> Aseptic loosening is a significant issue in the endoprosthetics of major joints of the lower limbs. In the modern view, aseptic loosening of joint prostheses is primarily caused by prolonged inflammation, which induces periprosthetic osteolysis. Various factors, such as sex, age, activity level, and others, can influence the development of periprosthetic osteolysis and aseptic loosening. Some researchers attribute to the factors gene polymorphisms related to inflammation, bone metabolism, and other processes. Understanding the connection between specific genetic markers and the development of endoprosthetic complications can provide deeper insights into the mechanisms of periprosthetic osteolysis and aseptic loosening, as well as allow for better prediction of complications in patients.</p> <p><bold>The aim of the study</bold> — based on a literature review, to identify the role of individual genetic traits in the development of periprosthetic osteolysis and aseptic loosening of joint prostheses.</p> <p><bold>Methods<italic>.</italic></bold> The search for original studies was conducted in the PubMed, Google Scholar, and eLIBRARY databases using the following keywords: endoprosthetics, genetics, aseptic loosening, polymorphism. Relevance to the research topic was verified by titles and abstracts of the articles, followed by analysis of the full-text versions. Papers with no access to the full text were not assessed.</p> <p><bold>Results<italic>.</italic></bold> Polymorphisms in genes regulating inflammation, bone metabolism, differentiation, apoptosis, and cell division processes can influence the development of aseptic loosening. Among such genes are IL1B, IL6, RANK, OPG, FRZB, and others. Data from genome-wide association studies are contradictory and may suggest that genetic factors influencing aseptic loosening can differ among various populations.</p> <p><bold>Conclusions<italic>.</italic></bold> Individual genetic traits might play a significant role in the development of periprosthetic osteolysis and aseptic loosening of joint prostheses. Although several studies have identified genetic polymorphisms that presumably influence the development of loosening, further research is needed to verify these results and assess the possibility of extrapolating the findings to other populations.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Актуальность<italic>.</italic></bold> По современным представлениям, в основе асептической нестабильности эндопротезов суставов лежит длительно протекающее воспаление, вызывающее перипротезный остеолиз. На развитие перипротезного остеолиза и асептической нестабильности эндопротезов могут влиять различные факторы, такие как пол, возраст, уровень активности и другие. Ряд исследователей относит к таким факторам полиморфизмы генов, связанных с воспалением, костным метаболизмом и другими процессами. Понимание связи между определенными генетическими маркерами и развитием осложнений эндопротезирования может позволить глубже понять механизмы перипротезного остеолиза и асептической нестабильности, а также прогнозировать развитие осложнений у пациентов.</p> <p><bold>Цель исследования</bold> — на основе анализа литературы определить роль индивидуальных генетических особенностей пациента в развитии перипротезного остеолиза и асептической нестабильности эндопротезов суставов.</p> <p><bold>Материал и методы<italic>. </italic></bold>Поиск оригинальных работ проводился в базах данных PubMed, Google Scholar, eLIBRARY по ключевым словам: эндопротезирование, генетика, асептическая нестабильность, полиморфизм; endoprosthetics, genetics, aseptic loosening, polymorphism. Проверка на соответствие тематике исследования выполнялась по заголовкам и резюме статей, после чего проводился анализ полнотекстовых версий. Работы, полный текст которых не был доступен, не оценивались.</p> <p><bold>Результаты<italic>. </italic></bold>На развитие асептического расшатывания могут влиять полиморфизмы генов, регулирующих процессы воспаления, костного обмена, дифференцировки, апоптоза и деления клетки: IL1B, IL6, RANK, OPG, FRZB и другие. Данные исследований с полногеномным анализом ассоциаций противоречивы и могут свидетельствовать, что в различных популяциях генетические факторы, влияющие на асептическое расшатывание, могут отличаться.</p> <p><bold>Заключение<italic>.</italic></bold> Индивидуальные генетические особенности пациента могут играть значимую роль в перипротезном остеолизе и асептической нестабильности эндопротезов суставов. Несмотря на то, что в ряде исследований определены генетические полиморфизмы, предположительно влияющие на развитие нестабильности, требуются дополнительные исследования для проверки полученных результатов и оценки возможности экстраполировать полученные данные на другие популяции.</p></trans-abstract><trans-abstract xml:lang="zh"><p/></trans-abstract><kwd-group xml:lang="en"><kwd>endoprosthetics</kwd><kwd>genetics</kwd><kwd>aseptic loosening</kwd><kwd>polymorphism</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>эндопротезирование</kwd><kwd>генетика</kwd><kwd>асептическая нестабильность</kwd><kwd>полиморфизм</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Schwartz A.M., Farley K.X., Guild G.N., Bradbury T.L. Projections and Epidemiology of Revision Hip and Knee Arthroplasty in the United States to 2030. J Arthroplasty. 2020;35(6):79-85. doi: 10.1016/j.arth.2020.02.030.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Jones M.D., Buckle C.L. How does aseptic loosening occur and how can we prevent it? Orthop Trauma. 2020;34(3):146-152. doi: 10.1016/j.mporth.2020.03.008.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Gallo J., Goodman S.B., Konttinen Y.T., Wimmer M.A., Holinka M. Osteolysis around total knee arthroplasty: A review of pathogenetic mechanisms. Acta Biomater. 2013;9(9):8046-8058. doi: 10.1016/j.actbio.2013.05.005.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Goldring S.R., Schiller A.L., Roelke M., Rourke C.M., O’Neil D.A., Harris W.H. The synovial-like membrane at the bone-cement interface in loose total hip replacements and its proposed role in bone lysis. J Bone Joint Surg Am. 1983;65(5):575-584.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Willert H.G., Semlitsch M. Reactions of the articular capsule to wear products of artificial joint prostheses. J Biomed Mater Res. 1977;11(2):157-164. doi: 10.1002/jbm.820110202.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Tuan R.S., Lee F.Y.I., Konttinen Y.T., Wilkinson M.J., Smith R.L. What are the local and systemic biologic reactions and mediators to wear debris, and what host factors determine or modulate the biologic response to wear particles? J Am Acad Orthop Surg. 2008;16:42-48. doi: 10.5435/00124635-200800001-00010.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Zhu Y., Chiu K., Tang W. Review Article: Polyethylene Wear and Osteolysis in Total Hip Arthroplasty. J Orthop Surg. 2001;9(1):91-99. doi: 10.1177/230949900100900117.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Cristofolini L. Critical Examination of Stress Shielding Evaluation of Hip Prostheses. Crit Rev Biomed Eng. 2017;45(1-6):549-623. doi: 10.1615/CritRevBiomedEng.v45.i1-6.190.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Münch H.J., Jacobsen S.S., Olesen J.T., Menné T., Søballe K., Johansen J.D. et al. The association between metal allergy, total knee arthroplasty, and revision. Acta Orthop. 2015;86(3):378-383. doi: 10.3109/17453674.2014.999614.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Fahlgren A., Bostrom M.P., Yang X., Johansson L., Edlund U., Agholme F. et al. Fluid pressure and flow as a cause of bone resorption. Acta Orthop. 2010;81(4):508-516. doi:10.3109/17453674.2010.504610.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Noordin S., Masri B. Periprosthetic osteolysis: Genetics, mechanisms and potential therapeutic interventions. Canadian J Surg. 2012;55(6):408-417. doi: 10.1503/cjs.003711.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Balasubramanian H., Ananthan A., Rao S., Patole S. Odds ratio vs risk ratio in randomized controlled trials. Postgrad Med. 2015;127(4):359-367. doi: 10.1080/00325481.2015.1022494.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>López-Anglada E., Collazos J., Montes A.H., Pérez-Is L., Pérez-Hevia I., Jiménez-Tostado S. et al. IL-1β gene (+3954 C/T, exon 5, rs1143634) and NOS2 (exon 22) polymorphisms associate with early aseptic loosening of arthroplasties. Sci Rep. 2022;12(1):18382. doi: 10.1038/s41598-022-22693-0.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Gallo J., Mrazek F., Petrek M. Variation in cytokine genes can contribute to severity of acetabular osteolysis and risk for revision in patients with ABG 1 total hip arthroplasty: A genetic association study. BMC Med Genet. 2009;10:109. doi: 10.1186/1471-2350-10-109.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Gordon A., Kiss-Toth E., Stockley I., Eastell R., Wilkinson J.M. Polymorphisms in the interleukin-1 receptor antagonist and interleukin-6 genes affect risk of osteolysis in patients with total hip arthroplasty. Arthritis Rheum. 2008;58(10):3157-3165. doi: 10.1002/art.23863.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Kolundžić R., Orlić D., Trkulja V., Pavelić K., Trošelj K.G. Single nucleotide polymorphisms in the interleukin-6 gene promoter, tumor necrosis factor-α gene promoter, and transforming growth factor-β1 gene signal sequence as predictors of time to onset of aseptic loosening after total hip arthroplasty: Preliminary study. J Orthop Sci. 2006;11(6):592-600. doi: 10.1007/s00776-006-1069-y.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Malik M.H., Jury F., Bayat A., Ollier W.E., Kay P.R. Genetic susceptibility to total hip arthroplasty failure: A preliminary study on the influence of matrix metalloproteinase 1, interleukin 6 polymorphisms and vitamin D receptor. Ann Rheum Dis. 2007; 66(8):1116-1120. doi:10.1136/ard.2006.062018.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Fields J.K., Günther S., Sundberg E.J. Structural basis of IL-1 family cytokine signaling. Front Immunol. 2019;10:1412. doi: 10.3389/fimmu.2019.01412.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Dinarello C.A., Simon A., Van Der Meer J.W.M. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633-652. doi: 10.1038/nrd3800.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Kusano K., Miyaura C., Inada M., Tamura T., Ito A., Nagase H. et al. Regulation of Matrix Metalloproteinases (MMP-2, -3, -9, and -13) by Interleukin-1 and Interleukin-6 in Mouse Calvaria: Association of MMP Induction with Bone Resorption. Endocrinology. 1998;139(3):1338-1345. doi: 10.1210/endo.139.3.5818.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Gowen M., Wood D.D., Ihrie E.J., McGuire M.K.B., Russell R.G.G. An interleukin 1 like factor stimulates bone resorption in vitro. Nature. 1983;306(5941):378-380. doi: 10.1038/306378a0.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Akatsu T., Takahashi N., Udagawa N., Imamura K., Yamaguchi A., Sato K. et al. Role of prostaglandins in interleukin‐1‐induced bone resorption in mice in vitro. J Bone Mineral Res. 1991;6(2):183-190. doi: 10.1002/jbmr.5650060212.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Spolski R., Li P., Leonard W.J. Biology and regulation of IL-2: from molecular mechanisms to human therapy. Nat Rev Immunol. 2018;18(10):648-659. doi: 10.1038/s41577-018-0046-y.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Wang X., Lupardus P., LaPorte S.L., Garcia K.C. Structural biology of shared cytokine receptors. Annu Rev Immunol. 2009;27:29-60. doi: 10.1146/annurev.immunol.24.021605.090616.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Liao W., Lin J.X., Leonard W.J. Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy. Immunity. 2013;38(1):13-25. doi: 10.1016/j.immuni.2013.01.004.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Saleh K.J., Holtzman J., Gafni A., Saleh L., Davis A., Resig S. et al. Reliability and intraoperative validity of preoperative assessment of standardized plain radiographs in predicting bone loss at revision hip surgery. J Bone Joint Surg Am. 2001;83(7):1040-1046. doi: 10.2106/00004623-200107000-00009.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Müller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374(1):1-20. doi: 10.1042/bj20030407.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Kaur S., Bansal Y., Kumar R., Bansal G. A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors. Bioorg Med Chem. 2020;28(5):115327. doi: 10.1016/j.bmc.2020.115327.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Hunter C.A., Jones S.A. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448-457. doi: 10.1038/ni.3153.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Ishimi Y., Miyaura C., Jin C.H., Akatsu T., Abe E., Nakamura Y. et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol. 1990;145(10):3297-3303.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Gordon A., Southam L., Loughlin J., Wilson A.G., Stockley I., Hamer A.J. et al. Variation in the secreted frizzled-related protein-3 gene and risk of osteolysis and heterotopic ossification after total hip arthroplasty. J Orthop Res. 2007;25(12):1665-1670. doi: 10.1002/jor.20446.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>MacInnes S.J., Del Vescovo E., Kiss-Toth E., Ollier W.E., Kay P.R., Gordon A. et al. Genetic variation in inflammatory and bone turnover pathways and risk of osteolytic responses to prosthetic materials. J Orthop Res. 2015;33(2):193-198. doi: 10.1002/jor.22755.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Wedemeyer C., Kauther M.D., Hanenkamp S., Nückel H., Bau M., Siffert W. et al. BCL2-938C&gt;A and CALCA-1786T&gt;C polymorphisms in aseptic loosened total hip arthroplasty. Eur J Med Res. 2009;14(6):250. doi: 10.1186/2047-783X-14-6-250.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Aydin-Yüce T., Kurscheid G., Bachmann H.S., Gehrke T., Dudda M., Jäger M. et al. No Association of CALCA Polymorphisms and Aseptic Loosening after Primary Total Hip Arthroplasty. Biomed Res Int. 2018;2018:3687415. doi: 10.1155/2018/3687415.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Malik M.H., Bayat A., Jury F., Ollier W.E., Kay P.R. Genetic susceptibility to hip arthroplasty failure - Association with the RANK/OPG pathway. Int Orthop. 2006;30(3):177-181. doi: 10.1007/s00264-006-0074-2.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Kovács B., Vajda E., Nagy E.E. Regulatory effects and interactions of the Wnt and OPG-RANKL-RANK signaling at the bone-cartilage interface in osteoarthritis. Int J Mol Sci. 2019;20(18):4653. doi: 10.3390/ijms20184653.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Li Y., Toraldo G., Li A., Yang X., Zhang H., Qian W.P. et al. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood. 2007;109(9):3839-3848. doi: 10.1182/blood-2006-07-037994.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Baron R., Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19(2):179-192. doi: 10.1038/nm.3074.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Jiao Z., Chai H., Wang S., Sun C., Huang Q., Xu W. SOST gene suppression stimulates osteocyte Wnt/β-catenin signaling to prevent bone resorption and attenuates particle-induced osteolysis. J Mol Med. 2023;101(5):607-620. doi: 10.1007/s00109-023-02319-2.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Derynck R., Budi E.H. Specificity, versatility, and control of TGF-b family signaling. Sci Signal. 2019;12(570):5183. doi: 10.1126/scisignal.aav5183.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Konttinen Y.T., Waris V., Xu J.W., Jiranek W.A., Sorsa T., Virtanen I. et al. Transforming growth factor-beta 1 and 2 in the synovial-like interface membrane between implant and bone in loosening of total hip arthroplasty. J Rheumatol. 1997;24(4):694-701.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Stelmach P., Wedemeyer C., Fuest L., Kurscheid G., Gehrke T., Klenke S. et al. The BCL2-938C&gt;A promoter polymorphism is associated with risk for and time to aseptic loosening of total hip arthroplasty. PLoS One. 2016;11(2):e0149528. doi: 10.1371/journal.pone.0149528.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Mrazek F., Gallo J., Stahelova A., Petrek M. Functional variants of the P2RX7 gene, aseptic osteolysis, and revision of the total hip arthroplasty: A preliminary study. Hum Immunol. 2010;71(2):201-205. doi: 10.1016/j.humimm.2009.10.013.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Wilkinson J.M., Wilson A.G., Stockley I., Scott I.R., Macdonald D.A., Hamer A.J. et al. Variation in the TNF Gene Promoter and Risk of Osteolysis After Total Hip Arthroplasty. J Bone Miner Res. 2003;18(11):1995-2001. doi: 10.1359/jbmr.2003.18.11.1995.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Mavčič B., Antolič V., Dolžan V. Association of NLRP3 and CARD8 Inflammasome Polymorphisms With Aseptic Loosening After Primary Total Hip Arthroplasty. J Orthop Res. 2020;38(2):417-421. doi: 10.1002/jor.24474.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Yan Y., Hu J., Lu H., Wang W. Genetic susceptibility to total hip arthroplasty failure: A case-control study on the influence of MMP 1 gene polymorphism. Diagn Pathol. 2014;9(1):177. doi: 10.1186/s13000-014-0177-9.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Pan F., Hua S., Luo Y., Yin D., Ma Z. Genetic susceptibility of early aseptic loosening after total hip arthroplasty: The influence of TIMP-1 gene polymorphism on Chinese Han population. J Orthop Surg Res. 2014;9(1):108. doi: 10.1186/s13018-014-0108-1.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Malik M.H., Bayat A., Jury F., Kay P.R., Ollier W.E. Genetic Susceptibility to Total Hip Arthroplasty Failure-Positive Association With Mannose-Binding Lectin. J Arthroplasty. 2007;22(2):265-270. doi: 10.1016/j.arth.2006.02.163.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Hu J., Van den Steen P.E., Sang Q.X.A., Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov. 2007;6(6):480-498. doi: 10.1038/nrd2308.</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Murphy G., Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med. 2009;29(5):290-308. doi: 10.1016/j.mam.2008.05.002.</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Nagase H., Visse R., Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69(3):562-573. doi: 10.1016/j.cardiores.2005.12.002.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Takei I., Takagi M., Santavirta S., Ida H., Ishii M., Ogino T. et al. Messenger ribonucleic acid expression of 16 matrix metalloproteinases in bone-implant interface tissues of loose artificial hip joints. J Biomed Mater Res. 2000;52(4):613-620. doi: 10.1002/1097-4636(20001215)52:4&lt;613::AID-JBM5 &gt;3.0.CO;2-8.</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Sasaki K., Takagi M., Mandelin J., Takei I., Santavirta S., Ida H. et al. Quantitative analysis of mRNA expression of TIMPs in the periprosthetic interface tissue of loose hips by real-time PCR system. J Biomed Mater Res. 2001;58(6):605-612. doi: 10.1002/jbm.1059.</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Zhao B. TNF and Bone Remodeling. Curr Osteoporos Rep. 2017;15(3):126-134. doi: 10.1007/s11914-017-0358-z.</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Chiba J., Rubash H.E., Kim K.J., Iwaki Y. The characterization of cytokines in the interface tissue obtained from failed cementless total hip arthroplasty with and without femoral osteolysis. Clin Orthop Relat Res. 1994;(300):304-312.</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Lerner U.H., Ohlin A. Tumor necrosis factors α and β can stimulate bone resorption in cultured mouse calvariae by a Prostaglandin‐independent mechanism. J Bone Miner Res. 1993;8(2):147-155. doi: 10.1002/jbmr.5650080205.</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Horowitz S.M., Purdon M.A. Mediator interactions in macrophage/particulate bone resorption. J Biomed Mater Res. 1995;29(4):477-484. doi: 10.1002/jbm.820290407.</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Fan Z., Kitaura H., Ren J., Ohori F., Noguchi T., Marahleh A. et al. Azilsartan inhibits inflammation-triggered bone resorption and osteoclastogenesis in vivo via suppression of TNF-α expression in macrophages. Front Endocrinol (Lausanne). 2023;14:1207502. doi: 10.3389/fendo.2023.1207502.</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Al-Ansari M.M., Aleidi S.M., Masood A., Alnehmi E.A., Abdel Jabar M., Almogren M. et al. Proteomics Profiling of Osteoporosis and Osteopenia Patients and Associated Network Analysis. Int J Mol Sci. 2022;23(17):10200. doi: 10.3390/ijms231710200.</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Evans D.M., Ralston S.H. Nitric oxide and bone. J Bone Miner Res. 1996;11(3):300-305. doi: 10.1002/jbmr.5650110303.</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Afzal F., Polak J., Buttery L. Endothelial nitric oxide synthase in the control of osteoblastic mineralizing activity and bone integrity. J Pathol. 2004;202(4):503-510. doi: 10.1002/path.1536</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Hukkanen M., Corbett S.A., Batten J., Konttinen Y.T., McCarthy I.D., Maclouf J. et al. Aseptic loosening of total hip replacement: macrophage expression of inducible nitric oxide synthase and cyclo-oxygenase-2, together with peroxynitrite formation, as a possible mechanism for early prosthesis failure. J Bone Joint Surg. 1997;79(3):467-474. doi: 10.1302/0301-620X.79B3.7469.</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>Zhou D., Huang C., Lin Z., Zhan S., Kong L., Fang C. et al. Macrophage polarization and function with emphasis on the evolving roles of coordinated regulation of cellular signaling pathways. Cell Signal. 2014;26(2):192-197. doi: 10.1016/j.cellsig.2013.11.004.</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Deets K.A., Vance R.E. Inflammasomes and adaptive immune responses. Nat Immunol. 2021;22(4):412-422. doi: 10.1038/s41590-021-00869-6.</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Rathinam V.A.K., Fitzgerald K.A. Inflammasome Complexes: Emerging Mechanisms and Effector Functions. Cell. 2016;165(4):792-800. doi: 10.1016/j.cell.2016.03.046.</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Fu J., Wu H. Structural Mechanisms of NLRP3 Inflammasome Assembly and Activation. Annu Rev Immunol. 2023;41(1):301-316. doi: 10.1146/annurev-immunol-081022-021207.</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Tsu B.V., Fay E.J., Nguyen K.T., Corley M.R., Hosuru B., Dominguez V.A. et al. Running With Scissors: Evolutionary Conflicts Between Viral Proteases and the Host Immune System. Front Immunol. 2021;12:769543. doi: 10.3389/fimmu.2021.769543.</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>Yi Y.S. Functional crosstalk between non-canonical caspase-11 and canonical NLRP3 inflammasomes during infection-mediated inflammation. Immunology. 2020;159(2):142-155. doi: 10.1111/imm.13134.</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>Bockstiegel J., Engelhardt J., Weindl G. P2X7 receptor activation leads to NLRP3-independent IL-1β release by human macrophages. Cell Commun Signal. 2023;21(1):335. doi: 10.1186/s12964-023-01356-1.</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>Wallis R. Structural and Functional Aspects of Complement Activation by Mannose-binding Protein. Immunobiology. 2002;205(4-5):433-445. doi: 10.1078/0171-2985-00144.</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation>Van der Ende J., Van Baardewijk L.J., Sier C.F.M., Schipper I.B. Bone healing and Mannose-Binding Lectin. Int J Surg. 2013;11(4):296-300. doi: 10.1016/j.ijsu.2013.02.022.</mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation>Dong L., Wu J., Chen K., Xie J., Wang Y., Li D. et al. Mannan-binding lectin attenuates inflammatory arthritis through the suppression of osteoclastogenesis. Front Immunol. 2019;10:1239. doi: 10.3389/fimmu.2019.01239.</mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation>Koks S., Wood D.J., Reimann E., Awiszus F., Lohmann C.H., Bertrand J. et al. The Genetic Variations Associated With Time to Aseptic Loosening After Total Joint Arthroplasty. J Arthrop. 2020;35(4):981-988. doi: 10.1016/j.arth.2019.11.004.</mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation>Wang M., Xu S. Statistical power in genome-wide association studies and quantitative trait locus mapping. Heredity (Edinb). 2019;123(3):287-306. doi: 10.1038/s41437-019-0205-3.</mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation>MacInnes S.J., Hatzikotoulas K., Fenstad A.M., Shah K., Southam L., Tachmazidou I. et al. The 2018 Otto Aufranc Award: How Does Genome-wide Variation Affect Osteolysis Risk after THA? Clin Orthop Relat Res. 2019;477(2):297-309. doi: 10.1097/01.blo.0000533629.49193.09.</mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation>Brüggemann A., Eriksson N., Michaëlsson K., Hailer N.P. Risk of Revision After Arthroplasty Associated with Specific Gene Loci: A Genomewide Association Study of Single-Nucleotide Polymorphisms in 1,130 Twins Treated with Arthroplasty. J Bone Joint Surg. 2022;104(7):610-620. doi: 10.2106/JBJS.21.00750.</mixed-citation></ref></ref-list></back></article>
